Tsumura & Co. (4540.TO) saw its revenue climb to ¥145.18 billion during the first three quarters of the fiscal year, a steady increase from the ¥136.77 billion recorded during the same period in 2024. Despite this sales momentum, the company’s bottom line faced headwinds, with net profit for the period dropping to ¥23.15 billion, down from ¥26.57 billion a year earlier.

Profitability Under Pressure

The decline in profitability was reflected across all major financial indicators. Operating profit fell to ¥28.86 billion, compared to ¥32.38 billion in the previous reporting cycle. Similarly, pretax profit reached ¥31.91 billion, down from ¥35.15 billion, according to the company's financial filing. These figures resulted in earnings per share of ¥309.60, a decrease from the ¥349.88 posted in the prior year.

The company confirmed that these results were calculated based on Japanese accounting standards. While the firm successfully expanded its top-line reach, the disparity between revenue growth and profit suggests higher operational costs or shifting market dynamics within the Japanese healthcare sector.